Joseph Maakaron

Joseph Maakaron practices at Blood & Marrow Transplant Group of Georgia in Atlanta, Georgia.

Joseph Maakaron's NPI, 1417397316, was assigned on June 25, 2013. Joseph Maakaron holds Minnesota license 65694.

Joseph Maakaron's primary practice is Blood & Marrow Transplant Group of Georgia, at 5670 Peachtree Dunwoody Rd, Atlanta, GA 30342 in Fulton County. The practice phone is (404) 255-1930.

Joseph Maakaron's primary practice is Blood & Marrow Transplant Group of Georgia in Atlanta, Georgia. Joseph Maakaron is also affiliated with Northside Hospital Atlanta. The medical group on file is Blood & Marrow Transplant Group of Georgia. Dmand AI also links Joseph Maakaron to 1 more hospital, 5 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Joseph Maakaron practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Joseph Maakaron's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Joseph Maakaron is licensed in Minnesota.

CMS data shows 245 Medicare services from Joseph Maakaron across 3 procedure codes in 2024, for 82 Medicare patients. Medicare paid $18,311 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 82 Medicare patients who saw Joseph Maakaron in 2024. The largest group is 65 to 74, with 51 patients. 62% of them have high blood pressure, and 59% have high cholesterol. 26% are also on Medicaid. Their average risk score is 3.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Joseph Maakaron's median patient age at 64, with 46% women.

In 2024, Joseph Maakaron wrote 684 Medicare Part D claims for 72 patients. 78% of them were for generic drugs. CMS names the drug for 429 of them, across 18 drugs with 11 or more claims each, at $1,272,318 in total drug cost. In 2023, CMS named 262 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Joseph Maakaron for performance year 2024, reported as part of a group. Joseph Maakaron accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Joseph Maakaron as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 56 papers to Joseph Maakaron, published from 2012 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive and Graft vs Host Disease. Joseph Maakaron has published most often in Transplant Cell Ther. Joseph Maakaron's most frequent co-authors are Veronika Bachanova, MD, Daniel J. Weisdorf, MD and Najla Hatem El Jurdi, MD.

Dmand AI links Joseph Maakaron to 3 clinical trials. Conditions studied include Waldenstrom Macroglobulinemia, Lymphoma, Non-Hodgkin and Lymphoma.

CMS Open Payments shows 48 general payments to Joseph Maakaron from 15 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Bristol-Myers Squibb Company paid the most, $26,242.